DDDD Share Price Performance
Recent DDDD News & Updates
No updates
4D pharma plc Key Details
Last Reported Earnings
Dec 31, 2021
Next Reporting Earnings
n/a
- Earnings per share (EPS)
- -0.18
- Gross Margin
- 100.00%
- Net Profit Margin
- -4,448.19%
- Debt/Equity Ratio
- 36.5%
4D pharma plc Competitors
About DDDD
- Founded
- 2014
- Employees
- 106
- CEO
- WebsiteView website
4D pharma plc, together with its subsidiaries, develops live biotherapeutic products (LBPs) in the United Kingdom. The company develops therapeutic candidates, including MRx0518 for the treatment of cancer and immune-oncology diseases; MRx-4DP0004 for the treatment of asthma; MRx0029 and MRx0005 the treatment of central nervous system disorders; Blautix for irritable bowel syndrome; and Thetanix for pediatric crohn’s disease. It also develops products candidates, such as MRx1299 for solid tumors, MRx0006 for rheumatoid arthritis, and MRx0002 for multiple sclerosis. In addition, the company develops MicroRx platform to discover new LBP candidates for major diseases. 4D pharma plc has a collaboration agreement with Merck KGaA, Darmstadt, Germany and Pfizer to evaluate MRx0518; strategic collaboration agreement with University of Texas MD Anderson for discovery and development of LBPs in oncology; and Merck & Co., Inc. to conduct a clinical trial evaluating the combination of Keytruda, MRx0518 in patients with solid tumors, and to discover and develop LBPs for vaccines. The company was formerly known as Schosween 18 Limited. 4D pharma plc was incorporated in 2014 and is headquartered in Leeds, the United Kingdom.
U.K. Market Performance
- 7 Days: 1.6%
- 3 Months: 8.3%
- 1 Year: 6.8%
- Year to Date: 8.8%
The market has climbed 1.6% over the last week, with theHealthcare and Information Technology sectors leading the way. The market is up 6.8% over the last 12 months. Earnings are forecast to grow by 15% annually. Market details ›
Companies across the globe are beginning to pay attention to agentic AI. It’s also a term you’re likely to hear a lot during earnings season. In fact, it came up 26 times during...
Continue reading